Introduction: In recent years, the positron emission tomography combined with computed tomography (PET/CT) has changed and the treatment approaches in Hodgkin’s lymphoma (HL) patients have entirely improved. The main idea in several studies is the use of PET/CT and the International Prognostic Score (IPS) protocols in identification of patients within a high-risk group and potential early relapse/refractory disease. Materials and methods: This study was based on PET/CT evaluation and treatment strategies of patients from eight Centers of Hematology in Ukraine. The patients included were newly diagnosed with HL and were aged 67 years or younger. They received a treatment with ABVD or BEACOPP-14/esc or “switched-regimens” (ABVD + BEACOPP-esc/14, BEACOPP-esc/14 + ABVD). The primary endpoints were to assess a correlation between PET/CT findings at the time of diagnosis, response to the therapy and clinical outcome (relapse/death) for patients with early and advanced stages of HL. The secondary endpoints were to evaluate the relationship between IPS and PET/CT findings. Results: The study group included 106 patients. The overall response rate (ORR) was 90.5%. The ORR for patients with stages I–II was 96.5% (55/57) vs. 91% (41/45) for stage III–IV patients. In total, the disease progression occurred in 58.3% (7/12) of PET2+ patients and in 13.3% (12/90) of PET2− patients (P < 0.05). No significant difference was found between the event free survival (EFS) rate and IPS for patients with PET2+ vs. PET2−, (log-rank test; P = 0.4). The PET3− status was found in 88.8% (79/89) of the study group patients and 1.2% (10/89) had a PET3+ status (P < 0.05). Using the Cox regression, we confirmed a significant correlation between EFS with PET3 Deauville scale (DS) and IPS. Patients with DS 1–2, DS 3 and DS 4–5 had a 1-year event-free survival of 94.4%, 100% and 33%, respectively (HR 0.56; 95% CI 1.07–2.8; P < 0.02). Our multivariable analysis showed no statistically significant correlation between PET2+ and PET3+ status and extranodal involvement or large tumor burden. Conclusion: The results of using PET/CT in patients with primary HL demonstrated a high prognostic value of PET at the end of the treatment. In addition, we confirmed the predictive role of IPS prognostic model in the treatment outcome depending on PET status.
A Ukrainian multicenter prospective study of thevalue of PET/CT prognostic role in primary patients with Hodgkin’s lymphoma in a real-life cohort
- Authors: Olga Novosad, PhD.; Tanya Skrypets; Yan Pastushenko; Tetiana Kadnikova; Alex Gorbach; Viktor Kozlov ; Larisa Mykhalska; Viktoria Kosinova; Nina Kostiukova; Oksana Karnabeda; Viktoria Stratienko ; Mykola Novikov; Olena Oliinichenko O; Iaroslav Kmetyuk; Olga Karpova; Andrii Ashykhmin A; Olena Lukjanec; Iryna Kriachok